Brought to you by 
AlgoRx goes public through merger with Corgentech
22 Nov 2006
Executive Summary
Seven months after withdrawing its IPO, pain management company AlgoRx Pharmaceuticals agreed to a reverse-merger with Corgentech (focuses on inflammatory and infectious diseases and cancer) through a $133.6mm all-stock deal as an alternate way to go public.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
- Topical Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AlgoRx goes public through merger with Corgentech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice